Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

Five Alarm Bio Ltd.. (2/27/23). "Press Release: Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment". Cambridge.

Organisations Organisation Five Alarm Bio Ltd. (5 Alarm Bio, FAB)
  Organisation 2 o2h Ventures Ltd.
  Group o2h (Group)
Products Product healthy aging / anti-aging / rejuvenation drugs
  Product 2 venture capital
Index terms Index term Five Alarm Bio–SEVERAL: investment, 202302 seed financing round >£500k
  Index term 2 Five Alarm Bio–United Kingdom (govt): grant, 202202– Biomedical Catalyst grant £360m from Innovate UK for developm of chronic wound treatment
Persons Person Thomas, Janette (Five Alarm Bio 202302 CEO)
  Person 2 Shah, Sunil (o2h Discovery Ltd 201806 CEO)
     


> Investors include Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, and Angel investors, with support from KPMG Acceleris

> Funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across broad range of age-related diseases


Five Alarm Bio (FAB), a drug discovery company focused on novel approaches to anti-aging, announced today it has completed a seed investment round, raising over £500K GBP to further enable its pioneering research. Investors participating in the round include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom, as well as other Angel investors, with support from KPMG Acceleris. This funding follows a £360K Biomedical Catalyst grant from Innovate UK, awarded to FAB early last year to develop its technology as a treatment for chronic wounds.

Based on breakthrough advances in understanding of how age-associated chemical damage accumulates in cells and tissues, FAB is developing an innovative small molecule approach aimed at boosting our defences as we age, to ultimately extend the healthy lifespan of our bodies. Age-related diseases such as arthritis, sarcopenia and Alzheimer’s Disease are among the leading causes of disability and mortality across the developed world, and a major burden on health funding. Globally, the anti-aging therapeutics market is expected to reach $2.01 billion by 20301.

This investment will drive further research into FAB’s proprietary approach, testing new compounds for their ability to extend the healthy lifespan of cells in vitro and improve their function in disease-relevant models. By targeting an unexplored mechanism of aging, these compounds have the potential to delay or prevent the onset of a broad range of age-related diseases.

Dr Janette Thomas, CEO, Five Alarm Bio, said: “Whilst life expectancy has increased over recent years, our healthy lifespan has not kept up. Anti-aging science therefore has huge value. Here at FAB our proprietary approach aims to overcome this fundamental challenge to human health as we work to discover and develop new drugs for age-associated diseases. We would like to thank the investors in our seed funding round for their support, and for their confidence in our team and the potential of our approach.”

Sunil Shah, Co-founder, Five Alarm Bio, and CEO, o2h Ventures, commented: “FAB is at the forefront of the rapidly growing anti-aging therapeutics industry, with the potential to deliver new drugs that extend our healthy lifespan. We are delighted to have made this investment alongside Meltwind, Cambridge Angels, and SyndicateRoom. The combination of the scientific depth of our CSO, William Bains, alongside the practical execution skills of the CEO, Janette Thomas, provides a great team to discover and develop new drugs for age-associated diseases.”

Founded in 2016 by three highly experienced entrepreneurs, FAB is currently based in purpose-built lab facilities on the world-renowned Babraham Research Campus, Cambridge.

For more information, please visit: http://www.fivealarmbio.com/.


1. Press Release: Global Anti-aging Therapeutics Market worth $ 2.01 Billion by 2030 – Exclusive Report by Insight Analytics (2 September 2022)


ENDS


[photos]

Dr Janette Thomas
CEO, Five Alarm Bio

Sunil Shah,
Co-founder, Five Alarm Bio,
and CEO, o2h Ventures

Five Alarm Bio team
From left to right: William Bains
(CSO), Janette Thomas (CEO),
Peter Tyrer (Lead Scientist), and
Hannah Mizen (Research
Scientist)

For high-resolution images, please contact Zyme Communications.


Media Contact

Esmé Walters
Zyme Communications
T: +44 (0) 7377 543244
E: esme.walters@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please e-mail
info@zymecommunications.com. To view our privacy policy, please click here.


About Five Alarm Bio
www.fivealarmbio.com

Anti-ageing science has enormous potential. Age-related diseases such as immune and neurodegenerative diseases are among the leading causes of disability, suffering and death, and a significant burden on health funding.

Five Alarm Bio is developing a small molecule approach to boost the body’s defence against aging, based on a new understanding of how the chemical damage associated with age accumulates in cells. In addition to a broad range of age-related diseases, Five Alarm Bio sees the relevance of its platform for cosmeceuticals.

Founded in 2016 by three experienced entrepreneurs, Five Alarm Bio is based near Cambridge, UK, and is carrying out research at the Babraham Campus.


About Cambridge Angels
https://cambridgeangels.com/

Cambridge Angels is a leading UK business angel network providing smart capital from entrepreneurs to entrepreneurs. The collaborative Cambridge-based group, actively mentors and invests in innovative teams and their ideas, equipping generations of entrepreneurs to generate returns and help realise their full potential. The group has a strong ethos of backing merit and supporting entrepreneurship. Cambridge Angels members, most of whom are successful entrepreneurs, invest in a wide range of start-up and scale-up businesses with a particular focus on deep-tech, and tools and technologies supporting healthcare.


KPMG Acceleris
www.acceleris.com

KPMG Acceleris is an FCA-regulated Venture Capital Advisory house which delivers a range of fundraising and advisory services for entrepreneurs in the UK and internationally, with a strong track-record in life sciences and other sectors. The firm provides access for entrepreneurs to an active pool of investors to support investments of £1m to £30m+.


About Meltwind
www.meltwind.com

Meltwind Advisory are the due diligence and portfolio management team for Dr Jonathan Milner, founder and former Chief Executive Officer of Abcam. Jonathan invests as an Angel across the life sciences, supporting early-stage companies throughout their journey with investment and guidance.


About o2h Ventures
www.o2hventures.com

The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7-acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.


About SyndicateRoom
www.syndicateroom.com

SyndicateRoom is a venture capital firm that uses data and diversification to maximise return potential. To do this it created the Access EIS fund: a uniquely data-driven approach to investing in startups that co-invests with business angels identified as the best performers in the UK to gain access to the most promising investment opportunities.

   
Record changed: 2024-01-20

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top